Lexagene Holdings Inc. engages in the research, development, and commercialization of pathogen detection devices to the bio-chemical industry in the United States. The company is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Stock Exchange CVE
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
SymbolCVE:LXG
CUSIPN/A
PhoneN/A
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares58,914,000
Market CapC$63.63
Lexagene (CVE:LXG) Frequently Asked Questions
What is Lexagene's stock symbol?
Lexagene trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LXG."
What is the consensus analysts' recommendation for Lexagene?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexagene in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Lexagene's key competitors?
Some companies that are related to Lexagene include Palatin Technologies (PTN), EPIGENOMICS AG/S (EPGNY), Oncimmune (ONC), Profound Medical (PRN), Sernova (SVA), Co-Diagnostics (CODX), SQI Diagnostics (SQD), Parallax Health Sciences (PRLX), Cambridge Cognition (COG), LED Medical Diagnostics (LMD), 3D Signatures (DXD), GeneNews (GEN), Oxford Advanced Surfaces Gro (CRON), Genedrive (GDR) and Eternity Healthcare (ETAH).
Who are Lexagene's key executives?
Lexagene's management team includes the folowing people:
- Dr. John F. Regan, Founder, Chairman & CEO
- Mr. Darrel M. Rebeck, Pres & Director
- Mr. Jeffrey Mitchell, Chief Financial Officer
- Mr. Allan Fabbro, VP of Corp. Devel.
- Mr. Greg Dale, VP of Product Devel. & Manufacturing
Has Lexagene been receiving favorable news coverage?
News stories about LXG stock have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lexagene earned a news sentiment score of 0.17 on Accern's scale. They also gave news coverage about the company an impact score of 45.84 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Lexagene?
Shares of LXG and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Lexagene's stock price today?
One share of LXG stock can currently be purchased for approximately C$0.86.
How big of a company is Lexagene?
Lexagene has a market capitalization of C$63.63 million.
MarketBeat Community Rating for Lexagene (CVE LXG)
MarketBeat's community ratings are surveys of what our community members think about Lexagene and other stocks. Vote "Outperform" if you believe LXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
